TSR-033 is a Monoclonal Antibody owned by GSK, and is involved in 2 clinical trials, which are ongoing.

Monoclonal antibody elicits anti-neoplastic activity by inhibiting lymphocyte-activation gene 3 (LAG-3). LAG-3 is an inhibitory receptor that regulates T-cell function to promote tumoral immune escape. It also functions at multiple levels to ensure appropriate T-cell homeostasis, activation, and differentiation. The drug candidate targets the LAG-3 and inhibits the tumor-mediated immune suppression.

The revenue for TSR-033 is expected to reach a total of $1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the TSR-033 NPV Report.

TSR-033 was originated by AnaptysBio and is currently owned by GSK.

TSR-033 Overview

TSR-033 is under development for the treatment of colorectal cancer, non-small cell lung cancer and metastatic melanoma. It targets lymphocyte-activation gene 3 (LAG-3). The drug candidate is developed based on the (Somatic hypermutation) SHM-XEL technology. It is also under development for ovarian cancer and endometrial cancer. 

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.

Quick View – TSR-033

Report Segments
  • Innovator
Drug Name
  • TSR-033
Administration Pathway
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.